Skip to main content
OpenTrials
Completed

NCT Number: NCT02596412

Augmented Reality to Reduce Pain During Botulinum Toxin Injections in Cerebral-palsied Children

Children with cerebral palsy may benefit from treatment with botulinum toxin injections to decrease spasticity for improve function and quality of life. These injections cause repeated pain throughout childhood and may be the cause of post-traumatic stress despite drug and non-drug pain management. The Mini-Docs project of the French Red Cross has a module based on a digital device with augmented reality. Distracting the child, the use of this module on a tablet would reduce pain felt during botulinum toxin injections.

Completed

Looking for future studies?

Notify Me

Key information

Age range

3 year–8 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Médecine Physique et de Réadaptation pour Enfants de Bois-Larris - Croix-Rouge française, Lamorlaye, France

Loading trial locations.

About this study

Objective: To evaluate the effect of the use of a module with augmented reality (Mini-Docs) on pain during botulinum toxin injections in children with cerebral palsy aged from 3 to 8 years

Method: Randomized controlled trial comparing a group of children receiving the module with augmented reality of the Mini-Docs and drug pain management (nitrous oxide and medications), with a group of children receiving the usual care of pain management that combines drug pain management (nitrous oxide and medications) and distraction techniques. The device with the augmented reality module allows the child to add virtual content to the real images of the care. The pain will be assessed for each child 10 minutes after the injections, using a self-assessment scale (the Faces Pain Scale - Revised) or a heteroevaluation scale (the Face Legs Activity Cry Consolability scale given by the nurse). The study will be conducted in two centers of physical medicine and pediatric rehabilitation of the French Red Cross (Paris and Lyon).

Expected Results:

  • Decreasing children's pain during botulinum toxin injections
  • Decreasing anxiety in children and parents during injections
  • Increasing coping skills in children
  • Facilitating of the achievement of the therapeutic goal during injections

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Cerebral-palsied children, whose diagnosis of cerebral palsy was confirmed by a neurologist reported in the medical record
  • Aged 3 to 8 years (until the day before 9 years old)
  • With a functional level of Gross Motor Function Classification System (GMFCS) I, II, III or IV
  • Treated by TB injection (child with or without a history of TB injections)
  • With a sufficient level oral expression to respond to questionnaires and to interact with the nurse for the use of augmented reality device
  • Obtaining written parental consent and oral approval by the child

Exclusion criteria

  • Impossibility to assess pain during the session by the FLACC scale or FPS-R scale
  • Visual disturbances excluding to use of the augmented reality device
  • Severe cognitive impairment making it possible to answer questionnaires
  • Child of functional level child GMFCS V
  • Child with a specific request for distraction (eg if the child demands to watch a cartoon). This in order not to interfere with the coping strategies used by the child.
  • Refusal on the part of the parents to sign consent, and refusal on the part of child to use the tablet
  • Child not benefiting from social security coverage

Treatment and study plan

use the module with augmented reality (Mini-Docs) on tablet during TB injection

Other

Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology

Primary outcomes

  1. Pain during botulinum toxin (TB) injections

    Time frame: Assessment 10 minutes after TB injection

    Standardized pain scores will be calculated on a scale from 0 to 10 points using validated tools adapted to the age of the child: the Faces Pain Scale - Revised (FPS-R) and the Face Legs Activity Cry Consolability (FLACC). With each scale, patient scoring ≥ 4 is defined as painful.

Secondary outcomes

  1. Level of anxiety of cerebral palsied children before TB injection

    Time frame: Assessment up to 1h before TB injection and up to 1h after TB injection

    measured by the Modified Yale Preoperative Anxiety Scale Questionnaire (m-Ypas), completed by the parents accompanying the child before and after TB injections

  2. Level of parental anxiety accompanying the child during care

    Time frame: Assessment up to 1h before TB injection and up to 1h after TB injection

    It will be measured by the Stait Trait Anxiety Inventory (STAI) questionnaire before and after TB injections.

  3. Assessment of Mini-Docs acceptability

    Time frame: 7 days after TB injection

    Mini-Docs acceptability will be assessed by telephone interview with the parents of the intervention group 7 days after the of TB injection

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Collaborators

  • Fondation Apicil
  • Fondation Motrice

Registry information

Official study title

MINIDOCS : Contribution of Augmented Reality to Reduce Pain During of Botulinum Toxin Injections in Cerebral-palsied Children. A Randomized Controlled Trial

Acronym: MINIDOCS

Important dates

Study start
2015
Primary completion
2020
Study completion
2020
First posted
Nov 4, 2015
Registry last updated
May 6, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.